PF-219,061 is a drug that was under development by Pfizer which acts as a potent and highly selective agonist for the dopamine D3 receptor. It was under development as a potential medication for the treatment of female sexual dysfunction.Van Der Graaf et al. Selective Dopamine D3 Receptor Agonists for the Treatment of Sexual Dysfunction, WIPO Patent WO2003051370, granted to Pfizer It did not advance into clinical trials.
See also List of investigational sexual dysfunction drugs ABT-670 ABT-724 Cabergoline Bremelanotide Flibanserin Intrinsa Melanotan II OSU-6162 PF-592,379 Pramipexole Tibolone UK-414,495
References